Seraseq® NGS Reference Materials
Helps expedite development and better characterize NGS-based assays
Receive your quote directly from the manufacturer.
LGC Clinical Diagnostics are global leaders in clinical genomic assay implementation and routine quality control. Our portfolio of Seraseq® products enables the promise of clinical genomics with the design and manufacture of patient-like reference materials for use in the development, validation, and implementation of molecular next-generation sequencing (NGS) assays that support clinical evaluation and management of various diseases including somatic cancer, reproductive health, infectious disease, and inherited disease.
MRD workshop at AMP 2025 on tumor-agnostic testing and standardization challenges
This expert panel discussion that took place at the Association for Molecular Pathology (AMP) 2025 Annual Meeting & Expo, explores current advances and future challenges in minimal residual disease (MRD) testing using liquid biopsy technologies. Featuring leaders from academia, industry, and clinical diagnostics, the conversation highlights progress in detecting circulating tumor DNA at extremely low levels, alongside the need for improved sensitivity, specificity, and standardization.
The panel examines emerging approaches such as tumor‑naive MRD testing, multi‑omics integration, including epigenetics and fragmentomics, and the growing role of AI and large datasets in improving assay performance. Key topics also include clinical validation, regulatory challenges, and the potential of MRD testing to enable earlier intervention and more personalized cancer treatment.
